Century Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Century Therapeutics, Inc. (IPSC) reported Diluted Shares Outstanding (Weighted Average) of 205.78 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-12
- Century Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 205.78M shares, a 138.62% increase year-over-year.
- Century Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 193.47M shares, a 124.71% increase year-over-year.
- Century Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 87.06M shares, a 1.92% increase year-over-year.
- Century Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 86.46M shares, a 2.08% increase year-over-year.
- Century Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 86.56M shares, a 10.05% increase from fiscal 2024.
- Century Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 78.65M shares, a 32.60% increase from fiscal 2023.
- Century Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 59.31M shares, a 83.11% increase from fiscal 2022.
- Century Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 32.39M shares, a 0.00% change from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month | Weighted Average Number of Shares Outstanding, Diluted 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 205.78M shares 10-Q · filed 2026-08-12 | 199.66M shares 10-Q · filed 2026-08-12 | 162.10M shares derived: average of 3 quarters · filed 2026-08-12 | 143.19M shares derived: average of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | 193.47M shares 10-Q · filed 2026-05-13 | 140.27M shares derived: average of 2 quarters · filed 2026-05-13 | 122.33M shares derived: average of 3 quarters · filed 2026-05-13 | 113.31M shares derived: average of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | 87.06M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 86.76M shares derived: average of 2 quarters · filed 2026-03-12 | 86.59M shares derived: average of 3 quarters · filed 2026-08-12 | 86.56M shares 10-K · filed 2026-03-12 | |
| 2025-09-30 | 86.46M shares 10-Q · filed 2025-11-13 | 86.35M shares derived: average of 2 quarters · filed 2026-08-12 | 86.39M shares 10-Q · filed 2025-11-13 | 86.05M shares derived: average of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | 86.24M shares 10-Q · filed 2026-08-12 | 86.21M shares 10-Q · filed 2026-08-12 | 85.92M shares derived: average of 3 quarters · filed 2026-08-12 | 85.61M shares derived: average of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | 86.10M shares 10-Q · filed 2026-05-13 | 85.76M shares derived: average of 2 quarters · filed 2026-05-13 | 85.41M shares derived: average of 3 quarters · filed 2026-05-13 | 84.58M shares derived: average of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | 85.41M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 85.06M shares derived: average of 2 quarters · filed 2026-03-12 | 84.07M shares derived: average of 3 quarters · filed 2026-03-12 | 78.65M shares 10-K · filed 2026-03-12 | |
| 2024-09-30 | 84.70M shares 10-Q · filed 2025-11-13 | 83.40M shares derived: average of 2 quarters · filed 2025-11-13 | 76.39M shares 10-Q · filed 2025-11-13 | 72.27M shares derived: average of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | 82.09M shares 10-Q · filed 2025-08-14 | 72.19M shares 10-Q · filed 2025-08-14 | 68.13M shares derived: average of 3 quarters · filed 2025-08-14 | 65.96M shares derived: average of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | 62.30M shares 10-Q · filed 2025-05-15 | 61.15M shares derived: average of 2 quarters · filed 2025-05-15 | 60.58M shares derived: average of 3 quarters · filed 2025-05-15 | 60.25M shares derived: average of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | 60.00M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | 59.72M shares derived: average of 2 quarters · filed 2025-03-19 | 59.57M shares derived: average of 3 quarters · filed 2025-03-19 | 59.31M shares 10-K · filed 2025-03-19 | 57.76M shares 10-K · filed 2024-03-14 |
| 2023-09-30 | 59.45M shares 10-Q · filed 2024-11-05 | 59.35M shares derived: average of 2 quarters · filed 2024-11-05 | 59.09M shares 10-Q · filed 2024-11-05 | 33.54M shares derived: average of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | 59.25M shares 10-Q · filed 2024-08-08 | 58.90M shares 10-Q · filed 2024-08-08 | 24.90M shares derived: average of 3 quarters · filed 2024-08-08 | 33.17M shares derived: average of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | 58.61M shares 10-Q · filed 2023-05-11 | 7.73M shares derived: average of 2 quarters · filed 2024-03-14 | 24.48M shares derived: average of 3 quarters · filed 2024-03-14 | 32.78M shares derived: average of 4 quarters · filed 2024-03-14 | |
| 2022-12-31 | -43.15M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 7.41M shares derived: average of 2 quarters · filed 2024-03-14 | 24.17M shares derived: average of 3 quarters · filed 2024-03-14 | 32.39M shares 10-K · filed 2024-03-14 | 57.76M shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 57.97M shares 10-Q · filed 2023-11-09 | 57.83M shares derived: average of 2 quarters · filed 2023-11-09 | 57.57M shares 10-Q · filed 2023-11-09 | 56.94M shares derived: average of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | 57.69M shares 10-Q · filed 2023-08-09 | 57.37M shares 10-Q · filed 2023-08-09 | 56.60M shares derived: average of 3 quarters · filed 2023-08-09 | 56.07M shares derived: average of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | 57.05M shares 10-Q · filed 2023-05-11 | 56.05M shares derived: average of 2 quarters · filed 2023-05-11 | 55.53M shares derived: average of 3 quarters · filed 2023-05-11 | 44.66M shares derived: average of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | 55.06M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 54.76M shares derived: average of 2 quarters · filed 2023-03-16 | 40.52M shares derived: average of 3 quarters · filed 2023-03-16 | 32.39M shares 10-K · filed 2023-03-16 | |
| 2021-09-30 | 54.47M shares 10-Q · filed 2022-11-10 | 33.26M shares derived: average of 2 quarters · filed 2022-11-10 | 24.84M shares 10-Q · filed 2022-11-10 | 20.42M shares derived: average of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | 12.04M shares 10-Q · filed 2022-08-11 | 9.78M shares 10-Q · filed 2022-08-11 | 9.07M shares derived: average of 3 quarters · filed 2022-08-11 | 8.67M shares derived: average of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | 7.68M shares 10-Q · filed 2022-05-16 | 7.58M shares derived: average of 2 quarters · filed 2022-05-16 | 7.55M shares derived: average of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | 7.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | 7.48M shares derived: average of 2 quarters · filed 2022-03-17 | 7.48M shares 10-K · filed 2022-03-17 | ||
| 2020-09-30 | 7.48M shares 10-Q · filed 2021-11-10 | 7.48M shares 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |